Results 171 to 180 of about 730,259 (221)

Driving Drugs Deeper: Force‐Driven Microneedle Systems for Active Therapy and Their Road Towards Clinical Implementation

open access: yesSmall, Volume 22, Issue 55, 1 October 2026.
Force‐driven microneedles are presented as active therapeutic microdevices that overcome the diffusion limits of conventional patches. By integrating gas generation, magnetic actuation, cavitation, or iontophoresis, these systems drive payloads deeper into tissue, enabling faster, more controlled delivery and highlighting key design principles and ...
Majed Amini   +3 more
wiley   +1 more source

Frailty and Fitness in Older Adults With Acute Myeloid Leukemia: From Chronological Age to Multiparametric Assessment

open access: yesEuropean Journal of Haematology, Volume 117, Issue 4, Page 787-798, October 2026.
ABSTRACT Acute Myeloid Leukemia predominantly affects older adults, who often present with comorbidities, functional impairment, and frailty, limiting eligibility for intensive chemotherapy or allogeneic transplantation. Historically, treatment options were restricted to hypomethylating agents, low‐dose cytarabine, hydroxyurea, or supportive care, with
Antonella Bruzzese   +11 more
wiley   +1 more source

Bridging gaps in diabetic neuropathy care: A Delphi‐based regional consensus from the Gulf Cooperation Council

open access: yesJournal of Diabetes Investigation, Volume 17, Issue 10, Page 1643-1657, October 2026.
A three‐round Delphi consensus developed GCC‐specific, evidence‐based recommendations for diabetic peripheral neuropathy (DPN) and painful diabetic neuropathy (PND). The consensus emphasizes proactive screening, early multimodal management, and addressing regional barriers to improve early detection, optimize management, and enhance quality of life ...
Abdulrahman Alshaikh   +13 more
wiley   +1 more source

Safety of benfotiamine as a Novel food pursuant to Regulation (EU) 2015/2283 and the bioavailability of benfotiamine as a source of thiamin in the context of Directive 2002/46/EC on food supplements

open access: yesEFSA Journal, Volume 24, Issue 10, October 2026.
Abstract Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on the safety of benfotiamine as a novel food (NF) pursuant to Regulation (EU) 2015/2283 and on the bioavailability of benfotiamine as a source of thiamin in the context of Directive 2002/46/EC ...
EFSA Panel on Nutrition   +27 more
wiley   +1 more source

An Unusual and a Rare Cause of Toxic Optic Neuropathy – Closantel Toxicity

open access: yesAnnals of Indian Academy of Neurology
Reshma Sultana Shaik   +3 more
openaire   +3 more sources

Methanol Induced Toxic Optic Neuropathy

open access: yesNeuro-Ophthalmology Japan, 2016
openaire   +1 more source

Cuban Epidemic Optic Neuropathy and its Relationship to Toxic and Hereditary Optic Neuropathy

open access: yesSeminars in Ophthalmology, 2010
The similarities and differences between toxic/nutritional and hereditary optic neuropathy and the pathophysiologic mechanisms that they have in common are described. This is based on data from the epidemic suffered in Cuba in 1992, which affected the optic nerves of many individuals and the experience of the authors in dealing with various toxic optic
Rosaralis, Santiesteban-Freixas   +5 more
exaly   +4 more sources

Toxic optic neuropathy

Current Neurology and Neuroscience Reports, 2003
Toxic optic neuropathy is a complex, multifactorial disease potentially affecting individuals of all ages, races, places, and economic strata. Etiology includes nutritional, environmental, toxicologic, and genetic factors. Most cases of nutritional amblyopia are encountered in disadvantaged countries.
Anat Kesler
exaly   +3 more sources

Ciprofloxacin-induced toxic optic neuropathy

Clinical and Experimental Ophthalmology, 2007
AbstractA case of bilateral toxic optic neuropathy that developed in the setting of prolonged oral ciprofloxacin use for the treatment of chronic osteomyelitis is described. The patient experienced progressive, bilateral and symmetrical visual loss, central scotomas and loss of colour vision over a 2‐month period.
Nadeeka Samarakoon   +2 more
exaly   +2 more sources

Home - About - Disclaimer - Privacy